Crossmark

First trimester screening for pre-term preeclampsia combining placental growth factor and cell-free DNA fetal fraction: development of a preliminary theoretical model

Crossref DOI link: https://doi.org/10.1007/s00404-026-08505-0

Published Online: 2026-09-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rabbi, Moran Landau https://orcid.org/0000-0002-4937-0542
Meiri, Hamutal https://orcid.org/0000-0002-2272-5139
Maymon, Ron https://orcid.org/0000-0002-2987-3847
Weiner, Chen https://orcid.org/0000-0001-6186-0379
Zehavi, Yonathan https://orcid.org/0009-0001-2667-9387
Abu-Hamed, Ramzia https://orcid.org/0000-0001-5523-999X
Chaim, Adina Bar

Benveniste-Levkovitz, Patricia

Cuckle, Howard https://orcid.org/0000-0003-2450-2403
Funding

Funding for this research was provided by:

Israeli Institute for Research in Maternal and Fetal Medicine (Haber Wolf Endowment (#307))

Tel Aviv University
License Information

Text and Data Mining valid from 2026-09-03

Accepted Manuscript valid from 2026-09-03
More Information

Article History

Received: 24 May 2026

Accepted: 16 June 2026

First Online: 3 September 2026

Declarations

Conflict of interest: Howard Cuckle has a financial interest, as a paid consultant of Revvity Inc., a provider of reagents and instruments for PlGF and cfDNA measurement. The other authors have no relevant financial or non-financial interests to disclose.

Ethical approval: Approval was obtained from Shamir Medical Center to evaluate preeclampsia risk for twins (ASF-0043-20) and later expanded to singletons (ASF-0043-24) using maternal factors and biomarkers.

Consent to participate: Women gave their written informed consent for screening and providing clinical information for the study.

Consent to publish: Not applicable.

Document is current

Any future updates will be listed below